research use only

Pimavanserin tartrate 5-HT Receptor inhibitor

Cat.No.S8183

Pimavanserin tartrate(ACP-103) is a potent and selective serotonin 5-HT2A inverse agonist with pIC50 of 8.73, used to treat psychosis associated with Parkinson’s disease.
Jump to

Quality Control

Batch: Purity: 99.86%
99.86

Solubility

In vitro
Batch:

DMSO : 100 mg/mL (99.48 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : 100 mg/mL

Ethanol : 25 mg/mL

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 1005.2 Formula

C50H68F2N6O4.C4H6O6

Storage (From the date of receipt)
CAS No. 706782-28-7 Download SDF Storage of Stock Solutions

Synonyms ACP-103 SMILES CC(C)COC1=CC=C(C=C1)CNC(=O)N(CC2=CC=C(C=C2)F)C3CCN(CC3)C.CC(C)COC1=CC=C(C=C1)CNC(=O)N(CC2=CC=C(C=C2)F)C3CCN(CC3)C.C(C(C(=O)O)O)(C(=O)O)O

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC50/Ki
5-HT2A
(cell-based assay)
8.7(pIC50)
In vivo

In rats, Pimavanserin (3 mg/kg, p.o.) attenuates DOI-induced head twitches. In mice, Pimavanserin (3 mg/kg, p.o.) significantly attenuates MK-801-induced hyperactivity. In a rat model of parkinsonian tremor, Pimavanserin (40 mg/kg, i.p.) produces a significant overall reduction of tacrine-induced tremulous jaw movements.

References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-08-31)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT07610135 RECRUITING
Mood (Psychological Function); Well Being; Mood; Healthy
Johns Hopkins University
2026-09-30 PHASE1; PHASE2
NCT06592833 RECRUITING
Major Depressive Disorder
Icahn School of Medicine at Mount Sinai
2025-02-25 PHASE2
NCT05999240 RECRUITING
Autism Spectrum Disorder
New York State Psychiatric Institute
2025-10-01 PHASE2
NCT04373317 RECRUITING
Parkinson's Disease Psychosis
VA Office of Research and Development
2022-10-24 PHASE4
NCT05441280 RECRUITING
Post-traumatic Stress Disorder; Insomnia
VA Office of Research and Development
2023-12-28 PHASE2
NCT05357612 RECRUITING
Neurodegenerative Diseases; Parkinson Disease; Parkinson Disease Psychosis
Vanderbilt University Medical Center
2023-01-23 PHASE4

Read more about Clinical Trials

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Signaling Pathway Map